Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates by Wille-Reece, Ulrike et al.
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There are no successful vaccines to prevent 
  tuberculosis, malaria, or HIV infection. In terms 
of immune correlates of protection for such in-
fections, it is likely that induction of antibodies, 
T cell responses, or both will be required (1). 
Live vaccines have been the gold standard for 
eliciting durable humoral and cellular responses 
in humans; however, despite the widespread 
use of Bacillus Calmette-Guerin as a vaccine 
against tuberculosis, it is not universally eff  ec-
tive for preventing pulmonary tuberculosis. 
Furthermore, although live-attenuated HIV 
vaccines have been shown to confer protection 
in nonhuman primates (NHP), they are pre-
cluded for use as the result of potential safety 
constraints (2). Hence, there is an urgent need 
to develop safe and eff  ective vaccine formula-
tions that can mimic or improve upon the im-
munogenicity elicited by live vaccines.
Currently, prime-boost immunization using 
a variety of heterologous vaccine formulations 
is an eff  ective approach for eliciting strong cell-
ular immune responses. In NHP, for example, 
vaccination with plasmid DNA–encoding HIV 
envelope or structural proteins followed by 
replication-defective adenovirus (rAD) encod-
ing the same proteins elicits protective re-
sponses against SHIV challenge (3, 4). Although 
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There is a remarkable heterogeneity in the functional profi  le (quality) of T cell responses. 
Importantly, the magnitude and/or quality of a response required for protection may be 
different depending on the infection. Here, we assessed the capacity of different Toll like 
receptor (TLR)-binding compounds to infl  uence T helper cell (Th)1 and CD8+ T cell re-
sponses when used as adjuvants in nonhuman primates (NHP) with HIV Gag as a model 
antigen. NHP were immunized with HIV Gag protein emulsifi  ed in Montanide ISA 51, an 
oil-based adjuvant, with or without a TLR7/8 agonist, a TLR8 agonist, or the TLR9 ligand 
cytosine phosphate guanosine oligodeoxynucleotides (CpG ODN), and boosted 12 wk later 
with a replication-defective adenovirus-expressing HIV-Gag (rAD-Gag). Animals vaccinated 
with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist had higher frequen-
cies of Th1 responses after primary immunization compared to all other vaccine groups. 
Although the rAD-Gag boost did not elevate the frequency of Th1 memory cytokine re-
sponses, there was a striking increase in HIV Gag-specifi  c CD8+ T cell responses after the 
boost in all animals that had received a primary immunization with any of the TLR adju-
vants. Importantly, the presence and type of TLR adjuvant used during primary immuniza-
tion conferred stability and dramatically infl  uenced the magnitude and quality of the Th1 
and CD8+ T cell responses after the rAD-Gag boost. These data provide insights for design-
ing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses.
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this approach is promising, further improvements in immuno-
genicity are desirable. In particular, primary immunization 
with plasmid DNA vaccines elicits less robust T cell and anti-
body responses in humans than observed in rodents or NHP 
(5). Moreover, the capacity of rAD to induce T cell responses 
is limited by preexisiting immunity from prior adenoviral in-
fection of the same serotype (6, 7). Finally, the rAD itself will 
induce neutralizing antibodies, thereby restricting its use for 
further boosting. Hence, a nonlive vaccine that elicits potent 
humoral and cellular immune responses would be useful for 
optimizing the primary immunization and could also be use-
ful to sustain or enhance immunity after the rAD boost.
A recent strategy for developing such a vaccine formula-
tion is to combine protein antigen with adjuvants that have 
the capacity to activate DCs and B cells. Indeed, we have re-
cently shown that NHP immunized with HIV Gag protein 
and a Toll-like receptor (TLR)9 ligand (cytosine phosphate 
guanosine oligodeoxynucleotides [CpG ODN]), or a 
TLR7/8 agonist elicit increased Gag-specifi  c antibody and 
Th1 responses compared with immunization with HIV Gag 
protein alone (8). Importantly, animals immunized with HIV 
Gag protein conjugated to the TLR7/8 agonist had substan-
tially increased Th1 responses, as well as induction of CD8+ 
T cell responses, compared with animals immunized with 
HIV Gag protein and soluble TLR7/8 agonist (8). More-
over, the quality of such responses as defi  ned on the basis of 
IL-2, IFN-γ, or TNF-α production was distinct in NHP im-
munized with the conjugate vaccine. Such animals had a high 
frequency of polyfunctional Th1 and CD8+ T cells secreting 
all three cytokines after immunization. This study suggested 
that both the vaccine formulation and the use of specifi  c 
TLR agonists that have the capacity to activate distinct sub-
sets of DCs will have a critical infl  uence on the type of T cell 
responses generated in NHP.
In this report, we assessed the role of altering vaccine for-
mulation with HIV Gag protein and specifi  c TLR agonists in 
the context of prime-boost immunization with rAD-Gag in 
NHP. A specifi  c focus was how primary immunization infl  u-
enced the magnitude and quality of eff  ector and memory T cell 
responses after rAD-Gag boost. HIV Gag protein mixed with 
a TLR7/8, TLR8 agonist, or a TLR9 ligand and emulsifi  ed 
in Montanide ISA 51 (9), was administered once to animals 
as a primary immunization. This formulation provides a depot 
of antigen and adjuvant at the site of immunization. Animals 
were boosted with a rAD-Gag and the immune responses 
were assessed for up to1 yr. Multiparameter fl  ow cytometry 
was used to analyze the magnitude (quantity) of Gag-specifi  c 
IL-2, TNF-α, or IFN-γ–producing T cells as well as the qual-
ity of such responses as defi  ned by the composition of these 
cytokines in any combination at the single cell level. Overall, 
the data reveal that the specifi  c TLR adjuvant used during the 
primary immunization strongly infl  uences the T cell response 
profi  les in terms of magnitude, quality, and Th1/CD8 balance 
during prime-boost immunization. This study provides a tool 
for fi  ne-tuning the immune functions to elicit the optimal pro-
tective response needed for a given pathogen.
RESULTS
Sustained IFN-𝗄 and IL-2 responses are elicited 
after primary immunization
NHP were immunized once with HIV Gag protein emulsi-
fi  ed in Montanide, an oil-based adjuvant (Montanide/Gag), 
with or without a TLR7/8 or TLR8 agonist, or CpG ODN. 
We used TLR7/8, TLR8, and TLR9 agonists or ligands 
based on their ability to selectively activate plasmacytoid 
(TLR7/8 agonist or CpG ODN), conventional DCs 
(TLR7/8 or TLR8 agonist) or both (TLR7/8 agonist) in 
vitro (8). This approach allowed an assessment of how the 
activation of specifi  c DC subsets could infl  uence T cell responses
in vivo. 2 wk after immunization, there was a striking in-
crease in the frequency of IFN-γ–producing cells (>1,000 
SFC/106 cells) in NHP that received Montanide/Gag plus 
CpG ODN compared with animals immunized with Mon-
tanide/Gag alone (Fig. 1 A). Within 2 wk, such responses 
rapidly decreased and then remained stable through week 12. 
Immunization with Montanide/Gag and the TLR7/8, but 
not the TLR8 agonist also signifi  cantly enhanced the fre-
quency of IFN-γ–producing cells throughout 12 wk compared 
with responses in animals immunized with Montanide/Gag 
alone (Fig. 1 A). Of note, although the peak IFN-γ responses 
in animals immunized with the TLR7/8 agonist were lower 
than in animals immunized with CpG ODN, there was little 
decrease in such responses throughout the 12 wk. Together, 
these data are consistent with our previous study showing 
that the TLR7/8 agonist or CpG ODN, but not the TLR8 
agonist, are eff  ective adjuvants for enhancing IFN-γ  responses 
in NHP in vivo (8).
In contrast with what was observed for IFN-γ, the fre-
quency of IL-2–producing cells was similar in all groups at 
4 wk after immunization (Fig. 1 B). However, although the 
number of IL-2–producing cells remained increased in ani-
mals immunized with the TLR7/8, TLR8 agonist, or CpG 
ODN, they were markedly decreased over the following 
2 wk in animals immunized with Montanide/Gag only. Thus, 
all TLR adjuvants used in this study conferred durability to 
the IL-2 response. Finally, we were unable to detect Gag-
specifi  c IL-4–producing cells by ELISPOT analysis, or IL-4 
and IL-10 protein secretion from PBMCs in any of the vac-
cine groups after in vitro stimulation (unpublished data). 
Collectively, these data show that emulsifying HIV Gag pro-
tein in Montanide with CpG ODN or the TLR7/8 agonist 
induces potent and sustained IFN-γ or IL-2 responses after a 
single immunization. Frequencies of IFN-γ or IL-2–produc-
ing cells for the individual animals are shown in Figs. S1 and 
S2 (available at http://www.jem.org/cgi/content/full/jem. 
20052433/DC1).
IFN-𝗄 and IL-2 responses are increased after rAD-Gag boost
All NHP were boosted 12 wk after primary immunization 
with rAD-Gag. As a control, three animals that had not 
received a primary immunization with HIV Gag protein 
were immunized with rAD-Gag, allowing a comparison 
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frequency of IFN-γ–producing cells was dramatically in-
creased in NHP immunized with Montanide/Gag plus any 
of the TLR adjuvants compared with animals immunized 
with Montanide/Gag or rAD-Gag alone at 8 and 56 wk after 
boost (Fig. 1 C). Furthermore, animals immunized with 
Montanide/Gag plus the TLR7/8 agonist had increased 
numbers of IL-2–producing cells compared with all other 
groups for all time points after the boost (Fig. 1 D). It should 
be noted that one out of four animals immunized with CpG 
ODN or TLR7/8 agonist did not have an increased IFN-γ 
responses after the rAD-Gag boost. Thus, this limited a statis-
tical diff   erence compared with animals immunized with 
Montanide/Gag alone at some of the time points. Neverthe-
less, there were dramatic diff  erences in the other animals as 
shown in Figs. S1 and S2.
Assessment of Gag-specifi  c T cell cytokine responses 
by multiparameter fl  ow cytometry
To characterize how the magnitude and quality of the CD4+ 
or CD8+ T cell cytokine responses were altered during 
prime-boost immunization, 10-color fl  ow cytometric analy-
sis was used at 2, 6, and 10 wk after primary immunization, 
and 3 and 56 wk after the rAD-Gag boost. A gating tree from 
a representative animal immunized with Montanide/Gag 
plus the TLR7/8 agonist is shown in Fig. 2. CD4+ and CD8+ 
T cells were separated into CD45RA+CD95– and CD45RA–
CD95+. Expression of CD95 has been used as a specifi  c 
marker in NHP to distinguish between naive and memory 
cells (10). Essentially all cytokine-producing T cells were 
CD45RA–CD95+. This population was used to calculate the 
total magnitude and quality of the cytokine response, and 
will be referred to as memory cells. Within the gated CD4+ 
or CD8+ CD45RA–CD95+ memory T cell population, cells 
were segregated into IFN-γ– or IFN-γ+ cells and further as-
sessed for production of IL-2, TNF-α, or both. This analysis 
reveals seven functionally distinct populations producing 
IL-2, IFN-γ, and TNF-α individually or in any   combination. 
Together, such populations comprise 100% of the total CD4 
or CD8 memory cytokine response and are represented 
  pictorially by the pie charts to compare the quality of the 
  responses between groups.
The magnitude and quality of Th1 responses 
after prime-boost immunization
To fi  rst defi  ne the magnitude of the responses, the frequency 
of the total Gag-specifi  c  CD45RA–CD95+ CD4+ T cell 
Figure 1.  The frequency of IFN-𝗄 and IL-2–producing cells after 
immunization with HIV Gag protein and TLR agonists/ligands ad-
ministered in Montanide. NHP were immunized once with HIV Gag 
protein with or without CpG ODN, a TLR7/8 or TLR8 agonist emulsifi  ed in 
Montanide, and boosted with rAD-Gag at 12 wk after primary immuniza-
tion. PBMCs were analyzed for production of IFN-γ and IL-2 by ELISPOT 
assay at various times after primary immunization (A and B), or 3, 8, and 
56 wk after rAD Gag boost (C and D). As controls, animals immunized 
with PBS, the TLR8 agonist, or CpG ODN without HIV Gag protein were 
boosted with rAD-Gag. Shown are the means ± SD of fi  ve monkeys 
(A and B), four to fi  ve monkeys (C and D), or three monkeys (rAD-Gag only) 
per group. *, P < 0.05 compared with Montanide/Gag group. After pri-
mary immunization, background responses for IFN-γ and IL-2 in animals 
that received Montanide/PBS, or a TLR agonist alone without HIV Gag 
protein were <10 SFC/106 cells (not depicted).
Figure 2.  Phenotypic and functional characterization of memory 
T cells by multiparameter fl  ow cytometry. PBMCs were analyzed after 
primary immunization and rAD-Gag boost by multiparameter fl  ow cytom-
etry. CD4+ and CD8+ T cells are fi  rst segregated into CD45RA+CD95– and 
CD45RA–CD95+ T cells. Within the CD45RA–CD95+ CD4+ or CD8+ T cell 
population, cells were separated into seven distinct populations based on 
production of IFN-γ, IL-2, or TNF-α in any combination, represented 
pictorially by the pie charts.1252  TLR AGONISTS IN PRIME-BOOST IMMUNIZATION | Wille-Reece et al.
  cytokine responses comprising IL-2, IFN-γ, or TNF-α–
  producing cells are presented from individual animals from 
each vaccine group 6 wk after the primary immunization 
(Fig. 3 A), and 3 and 56 wk after the rAD-Gag boost (Fig. 3 B). 
Consistent with our ELISPOT data, immunization with 
Montanide/Gag and the TLR7/8 agonist induced the high-
est frequency of cytokine-producing memory T cells prior 
and after rAD-Gag boost. Importantly, administration of 
rAD-Gag did not increase the total frequency of memory 
CD4+ T cell cytokine responses in animals that had received 
a primary immunization (Fig. 3, B and C).
As described for Fig. 2, the quality of the CD45RA–
CD95+ CD4+ T cell cytokine response was determined on 
the composition of IL-2, IFN-γ, or TNF-α production at 
the single cell level. 2 wk after primary immunization,  35% 
of Th1 cells from NHP vaccinated with Gag/Montanide and 
CpG ODN or the TLR8 agonist produced IFN-γ only or 
IFN-γ and IL-2, whereas animals immunized with the 
TLR7/8 agonist had very few of such cells (Fig. 4 A). By 
6 and 10 wk after immunization, there were progressively 
fewer cells expressing IFN-γ with or without IL-2 in all vac-
cine groups; cytokine responses from animals immunized 
with a TLR adjuvant were mostly comprised of cells secret-
ing IL-2 and TNF-α. The percentage of cells positive for all 
three cytokines (IFN-γ, TNF-α, IL-2) remained stable in all 
vaccine groups from weeks 2 to 10 after primary immuniza-
tion (Fig. 4 A). Of note, NHP immunized with HIV Gag/
Montanide without a TLR adjuvant had a response mainly 
comprised of cells positive for IL-2 only, with very few IFN-γ–
producing CD4+ T cells (Fig. 4 A). Moreover, the low 
  frequencies of total cytokine-producing cells in these animals 
1 yr after the rAD-Gag boost (Fig. 3 B) shows that the addi-
tion of a TLR adjuvant during primary immunization provides 
durability to the Th1 response even after the rAD-Gag boost.
Although the magnitude of the memory Th1 cytokine 
response did not increase after the rAD-Gag boost (Fig. 3, 
B and C), there was a dramatic change in the quality of such 
responses, and this was strongly infl  uenced by the TLR ago-
nist used in the primary immunization. This was most evi-
dent 1 yr after the rAD-Gag boost in NHP immunized with 
Montanide/Gag and the TLR7/8 agonist, with a response 
comprised of  50% of polyfunctional cells producing IFN-γ, 
IL-2, and TNF-α (Fig. 4 B). Collectively, these data show 
Figure 3.  The magnitude of Gag-specifi  c CD4+ T cell cytokine 
responses after prime-boost immunization. PBMCs were analyzed by 
multiparameter fl  ow cytometry as described in Fig. 2. The frequency of 
total cytokine-producing CD45RA–CD95+ CD4+ T cells (IFN-γ, IL-2, or 
TNF-α) was analyzed at 6 wk after primary immunization (A) and 3 and 
56 wk after rAD Gag boost (B). Data are shown for the individual animals 
in each group (A and B), or as the means of the three to fi  ve animals per 
group (C) shown in A and B. N/A: nonapplicable.
Figure 4.  The quality of the Th1 response after prime-boost 
  immunization. The total CD45RA–CD95+ CD4+ T cell cytokine response was 
divided into seven distinct subpopulations producing any combination of 
IFN-γ, IL-2, or TNF-α (Fig. 2); these data are shown as the means of their 
respective percentages from those animals with suffi  cient responses to 
allow for a consistent assessment of the quality (n = 4 per group, except 
Montanide/Gag + TLR7/8 agonist at week 56 (n = 3 animals), Mon-
tanide/Gag + TLR8 agonist at week 2 (n = 2 animals) and week 56 (n = 5 
animals), rAD-Gag only group at weeks 2 and 56 (n = 2 animals), and 
Gag only at week 6 (n = 3 animals)). *, low number of positive events did 
not allow for a consistent qualitative assessment; N/A: nonapplicable. 
Additional analysis of the quality of the T cell responses from individual 
animals at 3 wk after rAD-Gag boost is shown in Fig. S3 (available at 
http://www.jem.org/cgi/content/full/jem.20052433/DC1).JEM VOL. 203, May 15, 2006   1253
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that TLR adjuvants administered during primary immuni-
zation markedly aff  ected the quality and stability of the Th1 
response before as well as after the rAD-Gag boost.
The magnitude and quality of Gag-specifi  c CD8+ T cell 
cytokine responses after immunization
In addition to generating Th1 responses, it would be desirable 
if a nonlive vaccine could also elicit CD8+ T cell responses. 
Indeed, we have recently shown that antigen-specifi  c 
CD8+ T cell responses are induced in NHP after several 
  immunizations with HIV-Gag protein conjugated to the 
TLR7/8 agonist, but not when the protein was administered 
with the free TLR7/8, TLR8 agonist, or CpG ODN (8). 
Consistent with this, animals immunized with Montanide/
Gag and the TLR7/8 agonist but not the TLR8 agonist or 
CpG ODN had detectable frequencies of cytokine-  producing 
CD45RA–CD95+ CD8+ T cells (IFN-γ, IL-2, or TNF-α) 
  after a single immunization (Fig. 5 A). Thus, the TLR7/8 
agonist is suffi   cient to mediate cross-presentation in NHP, 
provided that the vaccine formulation is optimized. After the 
rAD-Gag boost, there was a striking increase in the total 
Gag-specifi  c CD45RA–CD95+ CD8+ T cell cytokine re-
sponse in animals immunized with Montanide/Gag and any 
of the TLR adjuvants (Fig. 5, B and C) compared with ani-
mals immunized with Montanide/Gag alone. Moreover, ani-
mals immunized with the TLR7/8 agonist had the highest 
frequencies of cytokine-producing memory CD8+ T cells for 
at least 1 yr after the adenoviral boost.
With regard to the quality of such responses, animals immu-
nized with Montanide/Gag and the TLR7/8 agonist had 
40–60% of cells secreting all three cytokines (IFN-γ, IL-2, or 
TNF-α) from the peak at 3 wk, to the memory responses at 
56 wk after rAD-Gag boost (Fig. 6). The majority of 
CD45RA–CD95+ CD8+ T cells generated in NHP immu-
nized with Montanide/Gag and CpG ODN or the TLR8 
agonist produced IFN-γ and IL-2, or IFN-γ only after the 
boost. Of note, without a TLR adjuvant during primary 
Figure 5.  The magnitude of Gag-specifi  c CD8+ T cells after prime-
boost immunization. The frequency of cytokine-producing CD45RA–
CD95+ CD8+ T cells (IFN-γ, IL-2, or TNF-α) was analyzed at 6 wk after 
primary immunization (A), and 3 and 56 wk after rAD Gag boost (B) by 
multiparameter fl  ow cytometry as described in Fig. 2. Data are shown for 
the individual animals in each group (A and B), or as the means from the 
three to fi  ve animals per group (C) shown in A and B. N/A: nonapplicable.
Figure 6.  The quality of Gag-specifi  c CD8+ T cells after prime-boost 
immunization. The total CD45RA–CD95+ CD8+ T cell cytokine response 
was divided into seven distinct subpopulations producing any combina-
tion of IFN-γ, IL-2, or TNF-α (Fig. 2); these data are shown as the means 
of their respective percentages from the four animals per group, except 
rAD-Gag only (n = 2 animals), Montanide/Gag + TLR7/8 agonist at week 
56 (n = 3 animals), and Montanide/Gag + TLR8 agonist at week 56 (n = 5 
animals). *, low number of positive events did not allow for a consistent 
qualitative assessment.1254  TLR AGONISTS IN PRIME-BOOST IMMUNIZATION | Wille-Reece et al.
  immunization, such responses were not sustained after the 
rAD-Gag boost. These data show that the presence of a TLR 
agonist was also required to impart stability to memory CD8+ 
T cells after the rAD-Gag boost.
Prime-boost immunization generates a high frequency 
of central memory T cells
After exposure to antigen, two subsets termed eff  ector and 
central memory cells can be identifi  ed. Although both subsets 
have eff  ector function, there is evidence that CD8+ central 
memory T cells have a greater capacity to proliferate after 
secondary exposure to antigen. Such cells have been de-
scribed to be more effi   cient in mediating protection against 
pathogens in the mice (11) and NHP (12). For NHP, diff  er-
ential expression of CD28 within a memory population has 
been used to distinguish central and eff  ector memory cells 
(10). Thus, to assess whether the vaccines used in our study 
induced central or eff  ector memory cells, the total memory 
CD45RA−CD95+ CD4+ or CD8+ T cell cytokine response 
was further segregated into CD28+ (central memory) and 
CD28− (eff  ector memory) cells. There was a relatively small 
fraction of CD4+ eff  ector memory cells at 2 wk after primary 
immunization and 3 wk after rAD-Gag boost in animals vac-
cinated with Montanide/Gag and CpG ODN. 10 wk after 
primary immunization and 56 wk after rAD-Gag boost, es-
sentially all cytokine-producing Th1 cells were CD28+ cen-
tral memory cells (Fig. 7). Furthermore, there was a large 
number of cytokine-producing eff   ector memory CD8+ 
T cells at 3 wk after rAD-Gag boost; however, 1 yr after the 
boost, the majority of CD8+ memory T cells were central 
memory cells (Fig. 7). Overall, the prime-boost immuniza-
tion elicited a high frequency of central memory Th1 and 
CD8+ T cell responses throughout the course of the study.
Gag-specifi  c antibody responses 
after prime-boost immunization
Montanide has been shown to be an eff  ective adjuvant for 
enhancing antibody responses when administered with dif-
ferent protein vaccines (13, 14). Thus, we measured   endpoint 
Gag-specifi  c antibody titers throughout the course of prime-
boost immunization. Animals immunized with Montanide/
Gag alone had antibody titers of >10,000 after primary im-
munization that increased  1 log after the rAD-Gag boost 
(Fig. S4, available at http://www.jem.org/cgi/content/full/
jem.20052433/DC1). There was a signifi  cant increase in 
  antibody responses in NHP immunized with the TLR7/8 
agonist compared with animals immunized with Montanide/
Gag only. Animals immunized with rAD-Gag alone without 
prior priming injection had endpoint titers of 1:500 (unpub-
lished data). These data show that potent humoral and 
cellular immune responses can be generated with this vac-
cine regimen.
D  I  S  C  U  S  S  I  O  N 
TLRs expressed on antigen-presenting cells play a central 
role in controlling innate and adaptive immune responses 
  after exposure to infectious pathogens. Hence, TLRs repre-
sent potent targets for vaccine development. Here, we used a 
variety of TLR agonists in the context of a prime-boost vac-
cine regimen with HIV Gag as a model antigen and found 
that these immunizations can generate a dramatically diff  er-
ent magnitude, quality, and CD4/CD8 balance. The ability 
to more defi  nitely assess immune responses with multiparam-
eter fl  ow cytometry and to understand how vaccines or adju-
vants activate innate immunity will be important for vaccine 
development and will provide the tools necessary for gener-
ating the particular type of T cell response best suited to pro-
tect against a given pathogen.
As described previously, heterologous prime-boost im-
munization with plasmid DNA followed by rAD generates 
HIV Gag-specifi  c cellular immune responses in NHP (6). 
  Although DNA vaccines are promising, further   improvements 
in immunogenicity are desirable. In the present study, a sin-
gle immunization of HIV Gag/protein with a TLR7/8 ago-
nist generated T cell IFN-γ responses comparable to those 
induced after three immunizations of plasmid DNA encod-
ing HIV Gag protein (6).
Importantly, the TLR agonist used in the primary immu-
nization had a strong infl  uence on both the magnitude and 
quality of the response after the rAD boost. To optimize vac-
cine delivery, we used Montanide ISA51 as it is easily com-
bined with proteins and TLR adjuvants and has an established 
safety profi  le in humans (9). Notably, 12 wk after a single 
immunization with Montanide/Gag and either the TLR7/8 
agonist or CpG ODN, the magnitude of the Th1 responses 
was similar to responses in NHP 2 wk after four immuniza-
tions given without Montanide (8). Mechanisms that could 
account for the increased effi   ciency and immunogenicity by 
Figure 7.  Characterization of central and effector memory Gag-
specifi  c T cells after prime-boost immunization. Cells were gated on 
CD28 and CD95, and cytokine-producing cells (IFN-γ, IL-2, or TNF-α) 
were overlayed as colored dots on the total CD4 or CD8 distributions 
shown in gray. For each vaccine group, a representative animal is shown.JEM VOL. 203, May 15, 2006   1255
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the Montanide/TLR agonist include increased duration of 
antigen/adjuvant at the site of immunization or more syn-
chronous delivery to the APC (8). Thus, this type of vaccine 
formulation allows for more potent and durable cellular im-
mune responses from a single immunization, making it a po-
tentially cost eff  ective and practical modality.
A potential caveat to this approach is that animals immu-
nized with Montanide/Gag and the TLR7/8 agonist had lo-
cal reactivity at the site of injection as early as 2 wk after 
immunization that resolved after 12 wk. This reactivity is not 
a general feature associated with the TLR7/8 agonist because 
repeated administration of protein and TLR7/8 agonist with-
out Montanide elicited no local reactivity; the reactivity 
might be ameliorated by lowering the agonist or protein 
dose, or by intramuscular administration. Notably, CpG 
ODN enhanced T cell responses to protein and Montanide 
with little local reactivity. Indeed, such an approach has been 
used in humans to enhance CD8+ T cell responses to mela-
noma peptides (15).
The use of TLR agonists selective for activating plasma-
cytoid DCs (pDCs), conventional DCs (cDCs), or both in 
vitro provides insight into how such subsets may be infl  uenc-
ing T cell immunity in vivo. The fi  ndings that CpG ODN 
elicited potent CD4+ T cell responses suggests that activating 
pDCs may be suffi   cient for generating Th1 responses, possi-
bly through induction of IFN-α. Whether IFN-α produced 
by pDCs would also aff  ect antigen presentation through mat-
uration of other APCs (i.e., cDCs), or whether pDCs could 
directly present antigen to CD4+ T cells remains an open 
question. With regard to the role of cDCs, the TLR8 agonist 
was a poor adjuvant for generating Th1 responses in vivo de-
spite its potency for eliciting IL-12p70 in vitro (8). It should 
be noted, however, that NHP immunized with Montanide/
Gag and the TLR8 agonist had increased IL-2 responses after 
the primary immunization and higher CD8+ T cell responses 
after the rAD-Gag boost than animals immunized with Mon-
tanide/Gag alone. Thus, the TLR8 agonist did have func-
tional eff  ects on the T cell response in vivo. Although it 
remains possible that TLR agonists that activate cDCs only 
would not be suffi   cient for eliciting strong Th1 responses in 
primates in vivo, it is more likely that diff  erences in the sta-
bility or optimal dose of the TLR8 agonist when compared 
with the TLR7/8 agonist could explain its limited adjuvant 
eff  ect in vivo. Further studies with improved methods to ac-
tivate and specifi  cally target cDCs will clarify their role for 
eliciting Th1 responses in vivo. However, as the highest 
memory T cell responses were detected in NHP immunized 
with the TLR7/8 agonist, our data suggest that an adjuvant 
able to activate both pDCs and cDCs will be optimal for en-
hancing T cell immunity in vivo.
In addition to generating strong Th1 responses, most of 
the animals immunized with Gag and TLR7/8 agonist in 
Montanide also had detectable CD8+ T cell responses, pro-
viding evidence for cross-presentation. Similarly, animals im-
munized four times with HIV Gag protein conjugated to the 
TLR7/8 agonist without Montanide had detectable CD8+ 
T cell responses (8). Together, these data suggest that induc-
tion of CD8+ T cell responses in NHP with a protein   vaccine 
can be achieved with a TLR agonist capable of activating 
both pDCs and cDCs.
Another major emphasis of this study was to determine 
how diff  erent TLR agonists would alter the quality of mem-
ory T cell responses in a prime-boost regimen. 2 wk after 
primary immunization, animals that received Montanide/
Gag with CpG ODN had a striking increase in the frequency 
of IFN-γ–producing cells compared with animals immunized 
with Montanide/Gag and the TLR7/8 agonist. However, 
these responses quickly diminished and, by 12 wk, were sim-
ilar in both groups. The rapid decrease in the number of 
IFN-γ–producing cells in NHP immunized with CpG ODN 
may be explained by the quality of the CD4+ T cell responses 
2 wk after primary immunization. These animals had a high 
frequency of eff  ector memory cells producing only IFN-γ, 
which would likely undergo cell death (16). Alternatively, 
the dramatic decrease in CD4+/IFN-γ–producing cells in 
this vaccine group may be the result of redistribution of such 
cells to nonlymphoid organs. By 10 wk after primary immu-
nization, the quality of the memory CD4+ T cell responses 
was nearly identical in animals immunized with CpG ODN 
or the TLR7/8 agonist. However, the total number of IL-2–
producing cells was higher when the TLR7/8 agonist was 
administered (Fig. 1 B), and this vaccine group had the high-
est memory T cell responses after the rAD-Gag boost. 
  Collectively, these data suggest that although CpG ODN elicit 
better short-term eff  ector cells in the primary phase, they are 
less effi   cient for inducing “boostable” memory cells than the 
TLR7/8 agonist. Despite the extensive analysis used in the 
present study, we did not identify a phenotypic or functional 
marker of T cells that can predict this boosting potential. 
However, it is possible that the increased frequency of IL-2–
producing cells accounted for the enhanced magnitude and 
quality of the responses seen with the TLR7/8 agonist.
It is important to note that NHP immunized without a 
TLR adjuvant had an IL-2–dominated primary CD4+ T cell 
response (with or without TNF-α). After rAD-Gag   boosting, 
these animals did not show a sustainable increase in IFN-γ–
producing cells. This suggests that the primary immunization 
“imprints” the CD4+ T cell responses and limits their capac-
ity to further diff  erentiate into CD4+/IFN-γ–producing ef-
fector cells. This has direct relevance for designing vaccines 
against diseases requiring both humoral and cellular responses, 
such as malaria or HIV. In this regard, if a primary immuniza-
tion with a protein antigen were given with an oil-based or 
alum adjuvant without a TLR agonist, there would be effi   -
cient induction of antibody responses, but the potential of 
limiting the cellular response after a viral boost.
After the rAD-Gag boost, there was no increase in the 
frequency of the total CD4 memory responses in all groups 
of animals immunized with any of the TLR adjuvants. It is 
possible that the rAD-Gag boost induced further diff  erentia-
tion of the primary Th1 response, resulting in an increased 
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death (16), thereby off  setting the expansion of existing or the 
generation of new antigen-specifi  c cells. Because high doses 
of rAD-Gag effi   ciently induce IFN-γ–producing cells, it may 
be possible to enhance the magnitude of the total CD4 mem-
ory responses by using lower doses or by administering rAD 
by a diff  erent route.
In contrast with the CD4 response, the magnitude of the 
CD8 response dramatically increased in all NHP after the 
rAD-Gag boost. Primary CD8+ T cell responses were only 
detected from animals immunized with Montanide/Gag and 
the TLR7/8 agonist; in this group, the increased magnitude 
after the rAD-Gag boost may refl  ect expansion of these cells. 
However, it is likely that the presence of a Gag-specifi  c 
CD4+ T cell response signifi  cantly enhances the CD8 gener-
ation, even in animals without detectable primary CD8+ 
T cells (17–19). This would extend to animals immunized 
with Montanide/Gag and CpG ODN or the TLR8 agonists, 
which had dramatically higher levels of Gag-specifi  c CD8+ 
T cells after rAD boosting than animals that were not primed 
or those that were primed with Montanide/Gag alone.
Finally, the Montanide/Gag plus TLR7/8 agonist prim-
ing and rAD-Gag boosting induced a high frequency of poly-
functional cells producing IL-2, IFN-γ, and TNF-α; the 
high responses were sustained over 1 yr. Hence, these data 
suggest that activating both pDCs and cDCs with the TLR7/8 
agonist elicits polyfunctional Th1 and CD8+ T cells. Gener-
ating a high frequency of IL-2–producing Th1 and CD8+ 
T cells may indeed be desirable for an HIV vaccine. In this 
regard, individuals infected with HIV have better control of 
infection if their CD4+ and CD8+ T cells sustain their prolif-
erative and/or IL-2–producing capacity (20–24). A recent 
study extended this fi  nding by demonstrating that long-term 
nonprogressors had a signifi  cantly biased T cell response with 
more “polyfunctional” CD8+ T cells simultaneously capable 
of multiple eff  ector functions when compared with progres-
sors (27). Similarly, in the experimental mouse model of 
Leishmania major infection, vaccines that induce a high fre-
quency of CD4+ T cells simultaneously producing IL-2, 
TNF-α, and IFN-γ confer the best protection (unpublished 
data). Together, these results emphasize that multi-functional 
T cell responses will be benefi  cial for infections in which Th1 
or CD8+ T cells are mediating eff  ector functions. In the cur-
rent study, we could not determine whether the immune re-
sponses generated by the TLR agonist–HIV protein vaccines 
would be suffi   cient to mediate protection because HIV Gag 
responses do not protect against SIV challenge. Future studies 
using SIV rather than HIV Gag protein together with TLR 
agonists are planned to assess whether this type of vaccine 
regimen confers protection.
Overall, these data highlight the remarkable heterogene-
ity of T cell responses elicited by prime-boost immunization 
regimens. An important question for vaccine development is 
whether the quality of the immune response is a better pre-
dictor of effi   cacy than the magnitude of the response. To this 
end, we show that remarkably diff  erent types of T cell re-
sponses (cytokine profi  le, CD4/CD8 balance, as well as mag-
nitude) can be generated through the use of diff  erent TLR 
agonists. Our data provide a framework for using protein-
based vaccines with TLR agonists in combination with repli-
cation-defective viral-based boosting to induce long-lived 
polyfunctional Th1 and CD8+ T cell responses. The ability 
to generate a variety of durable T cell responses will be a 
  focus of future vaccine studies for infections such as HIV, 
  Mycobacterium tuberculosis, Plasmodium falciparum, or L. major.
MATERIALS AND METHODS
Animals. Indian rhesus macaques were stratifi  ed into comparable groups 
based on age, weight, sex, and frequency of naive T cells. Animals were 
maintained at the animal facility of the Walter Reed Army Institute of 
  Research/Naval Medical Research Center. All experiments were conducted 
according to the guidelines of the National Research Council, under proto-
cols approved by the Institutional Animal Care and Use Committee at the 
Walter Reed Army Institute of Research/Naval Medical Research Center 
and the National Institutes of Health.
Immunizations. NHP (n = 5/group) were immunized a single time in 
two separate sites of the back (s.c.) with 200 μg HIV Gag protein with or 
without 2 mg of CpG ODN, TLR7/8, or TLR8 agonist emulsifi  ed in 
Montanide ISA 51 (Montanide). As controls during the primary immuniza-
tion, a single monkey was immunized with Montanide/PBS without HIV 
Gag protein. In addition, there were three animals that received PBS, the 
TLR8 agonist or CpG ODN without Montanide, and these were also 
boosted later with rAD-Gag to control for the immunogenicity of boosting 
alone. To formulate these vaccines, 5 ml aqueous (200 μg HIV Gag protein 
plus 2 mg TLR ligand/agonist in PBS) plus 5 ml Montanide were aseptically 
homogenized to form emulsions as described previously (25). Montanide 
emulsions formed water-in-oil droplets and dispersed in an oil phase consist-
ing of Marcol 5 paraffi   n oil (Exxon Co.) and 2% (vol/vol) Montanide 80 
surfactant (SEPPIC, Inc.). All emulsions contained droplets with an average 
distribution of  1 micron, as per the manufacturer’s (SEPPIC, Inc.) recom-
mendation. 12 wk after primary immunization, animals were boosted with 
1010 particles of rAD-Gag intramuscularly (i.m.) in a volume of 1 ml into the 
right thigh, rectus femoris muscle. Clinical grade rAD-Gag, an adenovirus 
serotype 5 (Ad5), was obtained from GenVec.
Reagents. Cytosine phosphate guanosine oligodeoxynucleotides “C” class 
(CpG ODN, 2395) were purchased from Coley Pharmaceutical Group, the 
TLR7/8 agonist (3M-012), a structural analogue of 3M-003, and the TLR8 
agonist (3M-002) were provided by 3M Pharmaceuticals (26). Purifi  ed re-
combinant HIV Gag p41 protein (HXB2 isolate) was made by the Protein 
Purifi  cation Group at the National Cancer Institute. An extensive functional 
analysis excluded the presence of contaminating peptides in the HIV Gag 
protein preparation.
Preparation of PBMCs. PBMCs were isolated from fresh blood by Ficoll 
density centrifugation using Accuspin tubes according to the manufacturer’s 
instructions (Sigma-Aldrich). Cells were used immediately or following 
cryopreservation for ELISPOT analysis or intracellular FACS staining. 
  Similar results were seen using fresh or cryopreserved cells.
Detection of Gag-specifi  c  IFN-𝗄 and IL-2–producing cells by 
ELISPOT assay. The frequency of IFN-γ and IL-2–producing cells from 
PBMCs was determined by ELISPOT assay as described previously (8). 
In general, ELISPOT analysis was performed on all fi  ve animals in groups 
immunized with Montanide/Gag and any of the TLR adjuvants. As a result 
of the high titers of preexisting neutralizing antibody titers against the Ad5 
vector, one animal in each group immunized with the TLR7/8 agonist or 
CpG ODN was excluded from analysis for all time points after AD-Gag 
boost. In addition, there were only three animals in the group that received 
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Polychromatic fl  ow cytometry. 5 × 106 PBMCs were stimulated in 
complete RPMI 1640 for 6 h with 5 μg/ml αCD28-Ax680, αCD49d and 
Brefeldin A (10 μg/ml each) with or without 2 μg/ml HIV Gag peptides. 
After stimulation, cells were stained as described previously (8). In brief, 
cells were surface stained for CD4, CD8, CD95, and CD45RA; in addi-
tion, ethidium monoazide bromide (EMA; 1 μg/ml) was added to identify 
dead cells. Cells were incubated for 15 min in the dark at room tempera-
ture and were exposed for 10 min to fl  uorescent light to photolink the 
EMA to the DNA. After washing, fi  xing, and permeabilizing, cells were 
stained for IFN-γ, IL-2, TNF-α, and CD3. 6 × 105–106 cells were acquired 
on a BD LSR II (BD Biosciences) and FACS data were analyzed using FlowJo 
software (Tree Star).
Statistics. All group comparisons on ELISPOT analysis were done using 
Student’s t tests with unequal variances on log-transformed data. p-values of 
<0.05 were considered signifi  cant.
Online supplemental material. Fig. S1 shows the frequencies of IFN-γ–
producing cells for the individual animals depicted as means in Fig. 1. Fig. S2 
shows the frequencies of IL-2–producing cells for the individual animals de-
picted as means in Fig. 1. Fig. S3 shows the quality of the Th1 and CD8 
T cell response 3 wk after rAD-Gag boost for the individual animals depicted 
as means in Figs. 4 B and 6. Fig. S4 shows the antibody responses after im-
munization with HIV Gag and TLR agonists/ligands. HIV Gag-specifi  c an-
tibodies were detected in serum obtained from animals 12 wk after primary 
immunization and 3 wk after rAD-Gag boost. 96-well plates were coated 
with HIV Gag protein, serum samples were added in serial dilutions, and 
  after incubation with horseradish peroxidase–conjugated anti-IgG (BD 
Biosciences), plates were developed using TMB substrate-chromogen 
(DakoCytomation). *, P < 0.05 when compared with gag group. Online 
supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20052433/DC1.
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